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Abstract
Background: Given the global increase in the aging population and age-related diseases, the promotion of healthy
aging is one of the most crucial public health issues. This trial aims to contribute to the establishment of effective
approaches to promote cognitive and brain health in older individuals with subjective cognitive decline (SCD).
Presence of SCD is known to increase the risk of objective cognitive decline and progression to dementia due to
Alzheimer’s disease. Therefore, it is our primary goal to determine whether spermidine supplementation has a
positive impact on memory performance in this at-risk group, as compared with placebo. The secondary goal is to
examine the effects of spermidine intake on other neuropsychological, behavioral, and physiological parameters.
Methods: The SmartAge trial is a monocentric, randomized, double-blind, placebo-controlled phase IIb trial. The study
will investigate 12months of intervention with spermidine-based nutritional supplementation (target intervention)
compared with 12months of placebo intake (control intervention). We plan to recruit 100 cognitively normal older
individuals with SCD from memory clinics, neurologists and general practitioners in private practice, and the general
population. Participants will be allocated to one of the two study arms using blockwise randomization stratified by age
and sex with a 1:1 allocation ratio. The primary outcome is the change in memory performance between baseline and
post-intervention visits (12 months after baseline). Secondary outcomes include the change in memory performance
from baseline to follow-up assessment (18 months after baseline), as well as changes in neurocognitive, behavioral, and
physiological parameters (including blood and neuroimaging biomarkers), assessed at baseline and post-intervention.
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Discussion: The SmartAge trial aims to provide evidence of the impact of spermidine supplementation on memory
performance in older individuals with SCD. In addition, we will identify possible neurophysiological mechanisms of
action underlying the anticipated cognitive benefits. Overall, this trial will contribute to the establishment of nutrition
intervention in the prevention of Alzheimer’s disease.
Trial registration: ClinicalTrials.gov, NCT03094546. Registered 29 March 2017—retrospectively registered.
Protocol version: Based on EA1/250/16 version 1.5
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Background
Longer life expectancy has led to a growth of the older
population, with individuals aged 60 and older expected
to reach about 20% of the population in high-income
countries [1]. This demographic change is associated
with increased rates of age-related diseases, such as de-
mentia due to Alzheimer’s disease (AD). The most
prevalent form of late-onset dementia is expected to
triple by the year 2050 [2], which will pose a high social
and economic impact on patients, caregivers, and society
in general. Importantly, around one third of these cases
worldwide are attributed to potentially modifiable risk
factors [3]. The development of effective strategies that
help to prevent age- and disease-related worsening of
brain structure and function may thus provide signifi-
cant benefits for society and health-care systems.
Subjective cognitive decline: a target group for early
intervention
Subtle neuropathological alterations related to AD are
suggested to start decades before the onset of clinical
symptoms [4, 5]. One early sign of pathological brain
aging is the manifestation of subjective cognitive decline
(SCD). In cognitively unimpaired older individuals, the
presence of SCD is associated with a higher risk for ob-
jective cognitive decline and clinical progression to
symptomatic disease stages [6–9]. Moreover, individuals
with SCD harbor increased β-amyloid (Aβ) deposition
[10], gray matter volume reduction [11–13], and neural
dysfunction [14] in brain regions typically affected in
AD. Thus, SCD has been conceptualized to occur at a
late preclinical stage of AD [15], where aberrant brain
changes are present [16] in the absence of objective cog-
nitive impairment. This at-risk group is recognized as an
eligible target population for early intervention strategies
[15, 17], aiming to protect against neuropathological al-
terations, to restore functional and structural brain
health, and to maintain cognitive abilities as long as
possible.
Spermidine and its implication in healthy aging
Healthy lifestyle behaviors, including physical activity,
cognitive attainment, and a healthy diet, are proposed to
protect against age- and disease-related brain changes
and, thereby, preserve cognitive functioning [18–22].
Caloric restriction, among others, appears to be effective
to improve memory performance in the elderly [23] and
induce favorable neural changes in the hippocampal net-
work [24]. Novel candidate substances proposed to
mimic such beneficial effects in aging organisms are nat-
ural polyamines, in particular, spermidine and spermine
[25, 26]. Organic compounds play an important role in
the maintenance of basic cellular functions like cell
growth, survival, and proliferation [27]. Beyond these
“microscopic” actions, there is an indication that poly-
amines influence “macroscopic” systems underlying
learning and memory as well as age-related changes of
this cognitive function. In rodent models, polyamine
levels in the hippocampus are shown to be associated
with memory retrieval and formation [28] and change
with age in certain brain areas, including
medial-temporal memory structures [29]. Lastly, the re-
duction of spermidine in the brain of aged flies is paral-
leled by memory decline [30].
Given these observational findings, it has been hypoth-
esized that external supply of polyamines may protect
against age-related memory loss. Indeed, a first study in
aging fruit flies showed that spermidine-rich diet re-
stored endogenous spermidine levels and thereby res-
cued memory performance [30]. This beneficial effect of
spermidine intake appears to be mediated by several
protective pathways [31]. For example, spermidine may
act through autophagy to regulate synaptic transmis-
sion/plasticity [32] and clear cellular “waste” including
pathogenic protein aggregates [30]. Nutritional spermi-
dine is also associated with a number of
cardio-protective [33] and anti-inflammatory [34] ac-
tions, which may help to preserve higher-order brain
functions. Overall, these findings in aging model organ-
isms have suggested a promising role of spermidine in
the promotion of brain and cognitive health.
Spermidine supplementation in older adults with SCD:
initial evidence
Spermidine supplementation is thus proposed to open a
new avenue in the protection and restoration of memory
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abilities in higher age. This expected benefit is of par-
ticular need in older individuals at risk for the develop-
ment of dementia. It is, however, unknown whether the
memory-promoting effect of spermidine is detectable in
humans and to what extent this effect may be attributed
to the influence of spermidine on biomarkers of healthy
aging. An initial study showed that polyamine-enriched
diet over 2 months increased blood spermidine levels in
healthy middle-aged men [35]. Our group has conducted
a first 3-month phase IIa trial with nutritional spermi-
dine in 30 older adults with SCD (ClinicalTrials.gov
identifier NCT02755246). Trial outcomes demonstrated
high compliance, tolerance, and safety profiles as well as
preliminary efficacy of the administered spermidine-rich
plant extract [36, 37]. Specifically, we found a moderate
enhancement of memory performance, measured using
the mnemonic similarity task (MST) [38], in the
spermidine-treated group compared with placebo inter-
vention. This computer-based task is a sensitive measure
of subtle cognitive changes induced by targeted inter-
ventions in the memory system [39]. In the pilot trial,
we did not detect intervention effects on standard neuro-
psychological tests of memory or executive functions
[37]. At this point, longer-term intervention studies with
sufficient sample size are required to validate the thera-
peutic potential of nutritional spermidine against mem-
ory loss in older individuals and delineate possible
neurophysiological mechanisms of action.
Choice of comparator
A placebo comparator will be implemented in this study,
in correspondence with our previous trial [36]. The
present trial will use microcrystalline cellulose as a com-
parator condition. Beside randomization and double
blinding, placebo-controlled trials allow to minimize the
risk of bias and to maximize the verification of the effect
of the verum intervention [40]. Our placebo capsules
will be identical to the verum intervention in shape,
color, taste, and smell, but contain no active ingredients.
The World Health Organization (WHO) and the US
Food and Drug Administration (FDA) recognize that the
use of cellulose as a food additive is safe and well toler-
ated in animal models and humans.
Objective and purpose of the SmartAge trial
We will conduct a randomized controlled trial with a
12-month spermidine supplementation in cognitively
unimpaired older individuals with SCD (n = 100). The
primary objective of the SmartAge trial is to provide evi-
dence of a beneficial impact of nutritional spermidine on
memory performance (primary outcome) at the end of
the intervention, as compared with placebo. Second, we
aim to examine whether spermidine intake has positive
effects on memory performance after an additional
6-month follow-up period without further supplementa-
tion as well as on other age-relevant cognitive domains,
lifestyle behaviors, psycho-affective characteristics, and
perceived quality of life. This data will help to estimate
potential benefits of nutrition intervention on well-being
and everyday life. Third, this trial will identify possible
mechanisms of action underlying the proposed
spermidine-associated benefits on cognition using indica-
tors of autophagy, blood-based biomarkers, and neuroim-
aging parameters of brain structure and function. Finally,
the study will assess potential moderators of the interven-
tion effect, such as age-related neuropathologies as well as
genetic polymorphisms. Overall, the SmartAge trial aims
to establish a significant milestone in the implementation
of early intervention strategies in older individuals at risk
of dementia due to AD.
Methods: participants, intervention, and
outcomes
Trial design and setting
This is a monocentric, randomized, double-blind,
placebo-controlled phase IIb trial, carried out at the
NeuroCure Clinical Research Center, Charité – Universi-
tätsmedizin Berlin.
The trial includes 12months of intervention with
spermidine supplementation (target intervention) com-
pared with 12months of placebo intake (control interven-
tion). The trial will compare outcomes of the two
intervention groups, with participants randomized to one
of the two study arms. Randomization is performed block-
wise with a 1:1 allocation ratio. The SmartAge trial has
been approved by the responsible Institutional Review
Board and will be carried out in compliance with institu-
tional ethical standards and the Declaration of Helsinki.
Eligibility criteria
The main inclusion criteria for potential participants in
the SmartAge study are:
1. Age, 60–90 years
2. Presence of SCD in accordance with research
criteria, recommended by the international SCD-I
working group for studies on SCD [15]: the expres-
sion of subjective cognitive complaints for at least
6 months and associated concerns (worries), affirm-
ation to consult and/or previous consultation of a
doctor due to these symptoms, normal cognitive
performance, and no restrictions on activities of
daily living
3. Ability to provide written informed consent
4. Health insurance coverage to clarify possible
incidental findings
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We will exclude potential participants in case one or
more of the following criteria are present:
1. Dementia, according to the Diagnostic and
Statistical Manual of Mental Disorders, 4th Edition
(DSM-IV) [41]
2. Mild cognitive impairment (MCI), according to
clinical diagnostic criteria [42]
3. Severe or untreated medical disorders (advanced
cardiac or respiratory disease, severe liver, kidney or
metabolic diseases, untreated thyroid dysfunctions or
untreated diabetes mellitus), psychiatric disorders
(untreated depression, psychosis) or neurological
disorders (epilepsy, clinically manifest stroke)
4. Malignancies currently or as indicated by medical
history (exception: basalioma)
5. Drug abuse or alcohol dependency
6. Current polyamine substitution and/or participation
in respective intervention studies
7. Known intolerance or allergies to wheat germs,
gluten or histamine
8. Contraindications to imaging techniques:
claustrophobia, metallic implants (e.g., intracranial
metal clips), electronic devices (e.g., cardiac
pacemakers), or permanent tattoos
9. With regard to positron emission tomography
(PET) assessments (optional consent): participation
in another study with the use of ionizing radiation
within the last 3 months
10. With regard to muscle biopsy assessments (optional
consent): allergy or intolerance to the local
anesthetic (lidocaine), coagulation disorders,
current therapy with antiplatelet or anticoagulation
drugs (e.g., clopidogrel, aspirin, vitamin K
antagonist, new oral anticoagulant drugs) or
steroids, current thrombosis, or other severe
diseases of the lower extremities that precludes
muscle biopsy
In case written informed consent is provided and all
eligibility criteria are met, participants will be included
in the study.
Intervention
Participants will receive nutrition intervention over 12
months with either spermidine or placebo supplementa-
tion. The dietary supplement used in the target interven-
tion is a polyamine-rich plant extract [36], produced
using an extraction method developed and optimized by
TLL The Longevity Labs (Graz, Austria). The extraction
method will obtain polyamines from wheat germs with-
out the application of acids, organic solvents, and/or po-
tentially harmful chemicals. Wheat germs serve as raw
material for the extraction process, because they contain
a high concentration of polyamines, in particular,
spermidine [43].
The plant extract to be administered is mainly
enriched by spermidine and spermine (with 1.2 mg
spermidine and 0.6 mg spermine per 1 g extract). Fur-
thermore, 1 g of extract contains 0.2 mg putrescine, <
0.005 mg cadaverine, and 0.166 mg L-ornithine. In com-
bination with a normal diet, the intake of the planned
daily dose of 750 mg extract (even in the case of multiple
overdoses) is below the calculated no observed adverse
effects level (NOAEL) for humans of 29 mg/kg body
weight (bw)/day for cadaverine and putrescine [44]. This
is also the case for spermidine and spermine, where the
NOAEL is 13.5 mg/kg bw/day or 3.1 mg/kg bw/day [44].
The NOAEL for L-ornithine in humans is above 500mg/
kg bw/day [45], and thus remains unattainable in the
planned extract administration. The safety of the
spermidine-rich extract for the use in humans was eval-
uated prior to the SmartAge trial by a chemical analysis
(unpublished data) and a translational study on safety
and tolerability [36].
In the intervention group, the spermidine supplement
will be administered daily in the form of six capsules,
each containing 125 mg extract, resulting in a daily dose
of 750 mg extract or 0.9 mg spermidine, 0.5 mg sperm-
ine, 0.2 mg putrescine, < 0.004 mg of cadaverine, and
0.12 mg of L-ornithine. This amount of daily polyamine
intake accounts for an increase of approximately 10–
20% of the average spermidine intake in industrial coun-
tries [46]. The dosage is within the amount of poly-
amines administered in an earlier intervention study
[35], using approximately 10 mg/day of dietary spermi-
dine in humans. The amount would also be obtainable
by well-targeted diets (e.g., 200 g of cooked soybeans
[47]). The control group will receive placebo capsules,
six per day, filled with 750mg cellulose in sum.
Participants of both groups (spermidine and placebo) are
instructed to follow a regular capsule intake per day, two
capsules with each main meal (breakfast, lunch, dinner),
and to maintain their dietary habits during the time of
intervention. Participants will be supplied with capsules
throughout the intervention period. To ensure trial compli-
ance, we closely monitor capsule intake throughout the trial
(see the “Intervention period” section).
Assessment of study measures
Measures assessed at baseline
Assessments of following participant’s characteristics will
be conducted at baseline, summarized in Table 1: (a)
demographic information including age, civil status, and
education; (b) information on family history focused on
AD, other non-specified subtypes of dementia, idiopathic
Parkinson’s disease, and stroke; and (c) behavioral mea-
sures of subjective cognition function, lifelong
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Table 1 SmartAge study outcome assessment
Time point Measurement Mode V0 V1 V2 V3
Enrollment
Eligibility screening Telephone x
Screening assessment MMSE [85] On-site
paper
x x x
Logical Memory [53] On-site
paper
x x x
TMT A [54] On-site
paper
x x x
GDS [56, 86] On-site
paper
x x x
IADL [55] On-site
paper
x x x
Signed informed consent On-site x
Allocation/randomization x
Intervention
Assessments
Baseline variables
Demographic information Age, civil status, education On-site
paper
x
Family history Dementia, Parkinson disease, and stroke On-site
paper
x
Subjective cognitive function ECog-39 [87] On-site
paper
x
Lifestyle (lifelong) LEQ [88] At-home
paper
x
CAI [89] On-site
interview
x
Personality BFI-10 [90] On-site
paper
x
SVF-78 [91] On-site
paper
x
Hand preference Oldfield Hand Preference [92] On-site
paper
x
Premorbid IQ MWT [93] On-site
paper
x
Genetic markers APOE ε4 status On-site x
Cerebral PET (optional consent) Aβ status On-site x
Primary outcome
Memory MST [38] On-site
Computer
x x x
Secondary outcomes
Memory VLMT [94] On-site
paper
x x x
Doors and People [95] On-site
paper
x x x
Executive function Digit Symbol [96] On-site
paper
x x x
TMT B [54] On-site
paper
x x x
Block Tapping [97] On-site
paper
x x x
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Table 1 SmartAge study outcome assessment (Continued)
Time point Measurement Mode V0 V1 V2 V3
Stroop [98] On-site
paper
x x x
Attention Digit Span [96] On-site
paper
x x x
TAP [99] subtests: alertness and divided attention On-site
Computer
x x
Language Semantic/Phonemic Fluency [100] On-site x x x
Boston Naming Test [100] On-site
paper
x x x
Lifestyle (current)
Physical activity FKA [101] At-home
paper
x x x
Cognitive activity CAI Present [89] On-site
interview
x x x
Sleep quality PSQI [102] At-home
paper
x x x
Diet FFQ [33, 63] At-home
paper
x x x
MEDAS [103, 104] On-site
paper
x x x
FFL [19, 62] At-home
paper
x x x
Psycho-affective/worry PSWQ [105, 106] At-home
paper
x x x
RSQ-D [107] On-site
paper
x x x
STAI-G [108] On-site
paper
x x x
Quality of life SF-12 [109] On-site
paper
x x x
WHOQOL-BREF [110] At-home
paper
x x x
Autophagy markers from muscle
biopsy (optional consent)
LC3 I/II, p62 [72], EP300 [111], proteomics, metabolomics [73] On-site x x
Blood-based markers Polyamine levels [33], metabolomics, proinflammatory
biomarkers, and neurotrophin levels
On-site x x
Cerebral neuroimaging markers Brain structure, perfusion, function On-site x x
Exploratory outcomes
Subjective cognitive function ECog-39, adapted [87] On-site
paper
x x x
MMQ, adapted [112] On-site
paper
x x x
Cardiovascular risk factors Blood pressure, lipid profile, glucose metabolism On-site x x x
Muscle function/strength* SPPB [113] On-site x x x
Handgrip strength On-site x x x
*Only for participants, who consented to muscle biopsy
Abbreviations: Aβ β-amyloid, APOE apolipoprotein E, BFI-10 Big Five Inventory-10, CAI Cognitive Activity Interview, ECog Everyday Cognition Scales, FKA Freiburger
Fragebogen zur körperlichen Aktivität, FFL food frequency list, FFQ Food Frequency Questionnaire, GDS Geriatric Depression Scale, IADL Instrumental Activities of
Daily Living Scale, LEQ Lifetime Experience Questionnaire, MEDAS Mediterranean Diet Adherence Screener, MMQ Meta Memory Questionnaire, MMSE Mini-Mental
State Examination, MST Mnemonic Similarity Task, MWT Mehrfachwahl-Wortschatztest, PET positron emission tomography, PSQI Pittsburgh Sleep Quality Index,
PSWQ Penn State Worry Questionnaire, RSQ-D Response Styles Questionnaire—Deutsche Version, SF-12 Short Form Health Survey, SPPB Short Physical
Performance Battery, STAI-G State-Trait Anxiety Inventory, SVF-78 Stressverarbeitungsfragebogen, TAP Testbatterie zur Aufmerksamkeitsprüfung, TMT Trail Making
Test, VLMT Verbaler Lern-und Merkfähigkeitstest, WHOQOL-BREF World Health Organization Quality of Life
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experience, and personality traits. In addition, (d) physio-
logical measures of brain Aβ status, measured using
[18F] florbetaben (FBB) PET, and genotype informa-
tion on apolipoprotein E (APOE) ε4 status along with
other learning-relevant polymorphisms, measured
using genotyping of blood-derived deoxyribonucleic acid
(DNA), will be obtained. Note that potential changes in
demographic information and family history will be re-
corded throughout the trial.
Outcome measures
Assessments of study outcomes will be conducted at the
baseline visit and post-intervention visit (12 months after
baseline). Selected outcome measures will be assessed at
the follow-up visit (18 months after baseline). Primary
and secondary outcomes are summarized in Table 1.
Study outcomes will be collected in accordance with
standardized operational procedures (SOPs) and study
assessors that are blinded to the type of intervention.
Primary endpoint: The primary endpoint of this trial is
the change in memory performance between baseline visit
(V1) and post-intervention visit (V2). Memory perform-
ance is operationalized by mnemonic discrimination abil-
ity, to be assessed by the MST [38]. Mnemonic
discrimination performance is evaluated due to its estab-
lished sensitivity and robustness to memory deficits asso-
ciated with aging and neurodegenerative disease [48–50].
Moreover, this behavioral marker is closely tied to neural
dysfunction in the hippocampal memory network [48, 49]
and has been identified as a sensitive outcome measure in
older individuals at higher risk of AD [39].
The visual memory task is available for public download
(http://faculty.sites.uci.edu/starklab/mnemonic-similarity-
task-mst/) with multilingual instructions. Sets of
well-matched stimuli will be presented at baseline,
post-intervention, and follow-up visits respectively, with a
pseudorandomized order of stimuli within each set. The
MST consists of two phases: During the incidental encod-
ing phase, participants view images of everyday objects
and decide on each trial, whether the object is typically
found “outdoors” or “indoors.” During the subsequent rec-
ognition phase, images are repeated (repetition items),
randomly inter-mixed with novel images (foil items), and
images that are perceptually similar to those pictures seen
during the encoding phase (lure items). Participants will
be asked to indicate for each trial, whether the image was
“old”, “new” or “similar”. From the proportion of re-
sponses provided during recognition, a response
bias-corrected mnemonic discrimination index will be cal-
culated, similar to previous reports [37, 38, 48].
Secondary endpoints: Secondary outcomes include the
change in memory performance (operationalized by
mnemonic discrimination performance) between baseline
visit (V1) and follow-up assessment (V3, 18months after
baseline). Additional secondary endpoints (see Table 1)
are changes in the following outcome measures:
(a) Neuropsychological parameters on verbal and visual-
spatial memory, attention, executive functions, and
sensorimotor speed, assessed at V1, V2, and V3
(b) Behavioral parameters of lifestyle behaviors,
psycho-affective characterization and perceived
quality of life, assessed at V1, V2, and V3, as well as
(c) Physiological parameters including autophagy signaling
(measured in muscle biopsies), peripheral vascular
parameters (measured in blood), and parameters of
brain structure, perfusion, and function (measured
using cerebral magnetic resonance imaging [MRI]) to
be assessed at V1 and V2.
Finally, exploratory outcomes (see Table 1) of subject-
ive cognitive function, cardiovascular risk factors, as well
as muscle function and strength markers (available for a
sub-sample) will be evaluated.
Using moderator analysis, we will further assess
whether demographic factors (including sex), genetic
phenotype (including APOE), and presence of brain
pathology (including a positive brain Aβ status) affect
outcomes of the intervention.
Participant timeline
The SmartAge trial will involve five phases for each par-
ticipant: study enrollment, which included screening as-
sessment (V0), a baseline visit (V1), a 12-month
intervention period, a post-intervention visit (V2), and a
follow-up visit (V3). Trial phases are described below
and summarized in Fig. 1.
Enrollment (V0)
Individuals, who express interest in study participation, will
undergo following screening procedure to ensure study eli-
gibility. A standardized pre-screening interview conducted
over the phone will be administered to collect information
on medical and demographic data, on MRI/PET suitability,
and on suitability for muscle biopsy. During this interview,
the following questions will be asked to endorse the pres-
ence of SCD with associated concerns (worries), similar to
previous reports and recommendations [15, 51]. Question
1 will be “Do you feel that your cognitive performance has
become worse?” (German: “Haben Sie das Gefühl, dass
Ihre geistige Leistungsfähigkeit schlechter geworden ist?”,
possible answers: yes/no). In case of a positive answer to
question 1, question 2 will be asked: “Since when do you
have the feeling that your cognitive performance has gotten
worse?” (German: “Seit wann hat sich ihre geistige Leis-
tungsfähigkeit verschlechtert?”). In case the answer to
question 2 is at least 6months, question 3 will be asked:
“Are you concerned about this cognitive worsening?”
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(German: “Bereitet Ihnen diese Verschlechterung Sorgen?”,
possible answers: yes/no). In case of a positive answer to
question 3, question 4 will be asked: “Would you seek or
have you sought medical help due to this cognitive worsen-
ing?” (German: “Würden Sie diesbezüglich einen Arzt auf-
suchen bzw. haben Sie dies bereits getan?”, possible
answers: yes/no). Affirmative responses to diagnostic ques-
tions 1, 3, 4, and a duration of SCD for at least 6months
are mandatory for study inclusion.
Potential participants that meet inclusion criteria as eval-
uated during pre-screening will be invited for the on-site
screening visit to the Charité – Universitätsmedizin Berlin.
Each individual will receive a standardized screening assess-
ment, including neuropsychological tests and question-
naires, to certify the absence of objective cognitive
impairment and current psychiatric disorder (e.g., depres-
sion). Following measures will be used: (a) Mini-Mental
State Examination (MMSE) [52] score ≥ 26, (b) perform-
ance above − 1.5 standard deviation (SD) of age-adjusted
norms in the Logical Memory II subscale total delayed re-
call (Story A and B) [53], and the Trail Making Test (TMT)
A [54], (c) no deficits on selected items of the Instrumental
Activities of Daily Living Scale (IADL) [55], and (d) a Geri-
atric Depression Scale (GDS) [56] score ≤ 10. After success-
ful completion of the on-site screening assessment, eligible
participants will proceed to baseline assessment.
Baseline visit (V1)
The baseline visit will encompass a maximum of 4 days
with different assessments conducted on each day. On
day 1 (carried out immediately after screening, duration:
approx. 5 h with breaks), each participant will receive a
standardized medical examination that includes fasting
blood sampling and physical assessments. Next, a stan-
dardized neuropsychological test battery and a question-
naire battery will be administered (Table 1). On day 2,
each participant will undergo the MRI assessment (dur-
ation: approx. 2 h). On day 3, muscle tissue biopsy will
be carried out to determine autophagy signaling (op-
tional consent, duration: approx. 2–3 h, aiming for 25
participants). On day 4, a cerebral Aβ PET assessment is
performed (optional consent, baseline visit only, dur-
ation: approx. 2–3 h, aiming for 50 participants). After
completion of the baseline visit, participants will be ran-
domly assigned to one intervention arm. The Aβ PET
measurements will in most cases be conducted after
intervention has started, due to logistic reasons.
Intervention period
During the intervention, at 3 months, 6 months, and 9
months after the baseline visit (V1), telephone or on-site
interviews will be scheduled with each participant to ob-
tain information on participants’ physical and mental
Fig. 1 SmartAge study flowchart. Abbreviations: MRI: magnetic resonance imaging; PET positron emission tomography, SCD subjective cognitive decline
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well-being, trial compliance, changes in dietary habits,
and current medication intake. The study assessor will
also ask for possible adverse events (AEs) and serious
adverse events (SAEs). At 6 months after baseline, the
remaining capsules will be counted to monitor adher-
ence to capsule intake and new capsules for the next 6
months will be provided. Moreover, participants will be
asked for their subjective estimation of compliance to
intervention. At the post-intervention visit (V2), capsule
counting procedures and subjective estimation of com-
pliance will be repeated.
Post-intervention visit (V2)
The post-invention visit will take place at the end of the
12-month intervention period. Assessments of the
post-intervention visit will be conducted on a maximum
of 3 days, to be scheduled in close temporal proximity.
On day 1, the standardized screening assessment (see
Table 1) is re-administered to determine possible
changes in the SCD diagnostic criteria, followed by the
same assessments as for the baseline visit, that is, the
standardized medical examination, the standardized
neuropsychological test battery and questionnaire bat-
tery. In addition, participants will be asked to provide
qualitative feedback on the intervention. On day 2, the
MRI assessment will be carried out and on day 3, the
muscle tissue biopsy will be obtained (optional consent).
Follow-up visit (V3)
The follow-up visit will take place 18 months after base-
line visit. The visit will include following assessments:
standardized screening assessment, standardized medical
examination without blood draw, and adapted versions
of the standardized neuropsychological test battery and
questionnaire battery (see Table 1). The participants will
be asked to provide qualitative feedback on the
intervention.
Sample size
A power calculation was conducted to estimate the
number of participants required to detect a group differ-
ence in the primary outcome (i.e., mnemonic discrimin-
ation performance) at the end of the intervention.
Sample size estimation was based on behavioral data ob-
tained in a phase IIa pilot trial [37]. In this pre-study on
30 SCD participants (dropout: n = 2) and a 3-month
intervention period, we determined an effect size of
Cohen’s d = 0.65 on the group difference in change of
mnemonic discrimination performance between baseline
(V1) and the end of intervention (V2). Since this is a
first estimate of the effect size based on a small sample,
we based our sample size estimation for the present
phase IIb trial on a smaller effect size of Cohen’s d = 0.5.
To demonstrate a significant effect in the primary
outcome, 50 participants per group (including a 10%
dropout rate) need to be incorporated in the analysis
with an unpaired-sample t test (two-sided significance
level = 0.05, power 80%). Sample size estimation was
conducted using a conservative approach [57] based on
an unpaired-sample t test, even though the intended
analysis of the primary outcome will be performed using
analysis of covariance (ANCOVA) models. Case number
estimation was compiled with the R package “pwr” [58].
Recruitment
Study participants will be recruited from memory clinics,
neurologists, and general practitioners in private practice
in Berlin and from the general population in Germany
through advertisements.
Methods: assignment of intervention
Allocation
Participants will be randomly assigned to the spermidine
or the placebo group. A blockwise (block size of 6)
randomization sequence, stratified by age (60–70, 70–
80, and 80–90 years) and sex, will be generated using a
computer-based algorithm (http://www.randomization.
com/). Participant allocation will be performed at a 1:1
ratio by a study investigator without involvement in out-
come assessments.
Blinding
This trial will be double-blind, hence, participants and
study assessors will remain blinded to group assignment
until after the follow-up visit (V3; last participant, last
visit). Efficacy of blinding from the participants’ perspec-
tive will be determined by asking each participant at
post-intervention visit (V2) and follow-up visit (V3) to
provide guesses of the assigned intervention condition.
Methods: data collection, management, and
analysis
Data collection methods
Medical, neuropsychological, behavioral, and physio-
logical data will be collected from each participant. De-
tails on data collection procedures are provided below;
time points of collection are detailed in Table 1. To en-
sure the standardization of data collection, all study as-
sessors will undergo systematic training. Most data will
first be recorded on paper (see Table 1) and will be en-
tered into electronic records after each study visit with
quality checks ongoing throughout the study. Quality
control will be ensured through regular data monitoring.
Medical history and examination
Medical history assessment will include information on
demographics, past and current medication intake, and
family history. Subsequently, medical and neurological
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examinations will be conducted, including measure-
ments of systolic and diastolic blood pressure and heart
rate at rest. In addition, venous blood samples will be
taken. In order to additionally test the influence of
spermidine intervention on age-related sarcopenia,
muscle function and muscle strength will be assessed
(only of participants consented for the muscle biopsy).
Neuropsychological and behavioral batteries
The trial will include validated paper-and-pencil and
computer-based neuropsychological tests as well as behav-
ioral questionnaires (see Table 1). These instruments were
selected based on their sensitivity and relevance in the
study of aging and in correspondence with protocols of
ongoing studies [59–61]. The neuropsychological test bat-
tery will include tests on learning and memory, executive
functions, attention and working memory, as well as sen-
sorimotor speed. The questionnaire battery will comprise
measures of psycho-affective characteristics, lifestyle infor-
mation (dietary habits, cognitive attainment, and physical
activity), quality of life, and personality traits.
With regard to the nature of the trial, several ques-
tionnaires will be applied to collect nutritional informa-
tion from each participant. Specifically, these measures
will include the Food Frequency Questionnaire (FFQ),
the Mediterranean Diet Adherence Screener (MEDAS),
and a diet questionnaire that was previously adapted
from a qualitative food frequency list (FFL) used in sev-
eral German large-scale surveys [19, 62] (see Table 1).
Validity and reproducibility of the FFQ are well estab-
lished and based on the gold standard by Willett and
colleagues [63]. The FFQ was recently applied in the
study of Eisenberg and colleagues [33], indicating that
this questionnaire provides meaningful estimations
about the participant’s polyamine intake per day.
Questionnaires will be completed on-site and at home
by each participant. Trained raters will evaluate neuro-
psychological tests and questionnaires in accordance
with existing guidelines in test or questionnaire manuals.
If available, German versions of questionnaires are in-
cluded. Otherwise, German translations will be acquired
or provided by the DELCODE study [59].
Blood sampling, genotyping, and pre-analytics
Fasting venous blood samples will be collected to analyze
various blood parameters and to conduct genotyping.
Labor Berlin Charité Vivantes GmbH will perform ana-
lyses of blood samples for safety parameters and research
parameters, including glucose metabolism and lipid pro-
file, in accordance with established SOPs. Polyamine levels
(spermidine, spermine, and putrescine), metabolomics,
proinflammatory biomarkers, and neurotrophin levels in
whole blood, serum and plasma samples will be analyzed
by the Institute of Molecular Biosciences, University of
Graz, Austria. In addition, analysis of intracellular proteins
with focus on nutrient signaling, metabolic regulation,
and membrane-bound cellular markers of aging will be
measured in peripheral blood mononuclear cells (PBMCs)
extracted from whole blood [64]. In isolated leukocytes
obtained from blood samples, acetylation levels and au-
tophagy flux will be analyzed in collaboration with the
INSERM U1138, Centre de Recherche des Cordeliers,
Paris, France. Genetic analyses will be conducted by the
Department of Psychiatry, Martin Luther University,
Halle-Wittenberg, Germany.
Preprocessing and intermediate storage of blood sam-
ples will be performed at the Charité NeuroCure – Labs
and at the NeuroCure Clinical Research Center, Charité
– Universitätsmedizin Berlin. Blood samples for Labor
Berlin Charité Vivantes GmbH will be shipped immedi-
ately. All other samples will be stored at − 80 °C or at 4 °
C in phosphate-buffered saline and sodium azide until
shipment for further processing and analyses. NeuroHub
biomarker management platform and LabVantage soft-
ware will guarantee standardized workflows, documenta-
tion, and monitoring of pre-analytics including
processing as well as storage as described previously [36,
65].
Magnetic resonance imaging
The MRI examination will take place on a 3-T scanner
(Tim Trio, Siemens, Erlangen, Germany) at the Berlin Cen-
ter for Advanced Neuroimaging (BCAN, Charité – Univer-
sitätsmedizin Berlin). The SmartAge MRI protocol will
include structural and functional sequences (see Table 2).
For structural imaging, a T1-weighted three-dimensional
magnetization-prepared rapid acquisition gradient echo
(MPRAGE) sequence, a Fluid Attenuated Inversion Recov-
ery (FLAIR) sequence, Diffusion Tensor Imaging (DTI),
and a high-resolution T2-weighted structural scan will be
acquired perpendicular to the longitudinal axis of the
hippocampus. The protocol will further include the follow-
ing functional sequences: a blood-oxygen-level-dependent
(BOLD) functional echo planar imaging (EPI), as assessed
during rest (resting-state functional MRI) and during task
(task-related functional MRI), and pseudo-continuous ar-
terial spin labeling (pCASL) for cerebral blood flow (CBF)
quantification during rest [66, 67].
Functional MRI will include an associative face-name
memory task, adapted and modified from a previous pub-
lication [68]. During the scanning session, the participants
will learn 24 face-name pairs (encoding phase), which
have to be correctly identified in a subsequent recognition
phase. For details on this memory task, please refer to
Sperling and colleagues [69, 70].
All MRI scans will undergo quality checks and will be
evaluated quantitatively using state-of-the-art brain MRI
software packages and toolboxes implemented in Statistical
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Parametric Mapping (SPM, Wellcome Department of Im-
aging Neuroscience), FSL (FMRIB Software Library, Ox-
ford, UK), and FreeSurfer (Martinos Center for Biomedical
Imaging, Massachusetts General Hospital, Boston, USA).
Structural MRI scans will be used to examine the integrity
of cerebral gray and white matter tissues, including
assessments of volume, thickness, microstructure, and
high-resolution volumetric quantification of
medial-temporal structures [71]. Functional scans will be
analyzed to assess brain activation patterns during the asso-
ciative memory task as well as CBF maps and functional
connectivity at rest.
Muscle tissue biopsy and muscle function (optional consent)
Muscle tissue biopsy will be performed at the Clinical
Research Unit, Berlin Institute of Health (BIH, Charité –
Universitätsmedizin Berlin). In total, 200–400 mg muscle
tissue will be collected from the participant’s thigh
(Musculus vastus lateralis). For this purpose, local
anesthesia with lidocaine 1% without epinephrine will be
administered. Subsequently, a skin incision (3–4mm)
will be made and the muscle tissue will be obtained by
repeated needle biopsies (Bergström needle). Participants
are asked to fast prior to the procedure for at least 8 h.
After 12-month intervention time (V2) a second muscle
tissue biopsy will be carried out at the same leg close to
the first puncture site. Biopsy tissue processing will in-
clude snap freezing in liquid nitrogen and paraffin em-
bedding. Samples will be stored at − 80 °C until analysis.
Potential changes in muscle autophagy markers in re-
sponse to spermidine intervention will be quantified by
immunohistochemical analysis of autophagic flux and
autophagic capacity [72] as well as by acetylproteome
analysis as an upstream regulator of autophagy [73].
In addition, non-invasive measurements of muscle func-
tion and muscle strength will be assessed during medical
examination from all participants who consented to
muscle biopsy, to determine age-related sarcopenia. For
this purpose, the following standardized measurements of
sarcopenia will be administered: Short Physical Perform-
ance Battery (SPPB) [74, 75], and a handgrip strength test
[75]. The SPPB is a composite measure and will include
4-m gait speed, balance, and chair stand tests.
Positron emission tomography (optional consent)
Quantification of brain Aβ status is carried out using PET
and the approved ligand FBB (Neuraceq™; Life Molecular
Imaging (LMI)). The FBB PET images will be acquired
using the PET/MR hybrid system (Siemens Biograph
mMR) of the Institute of Diagnostic and Interventional
Radiology and Nuclear Medicine, Charité – Universitäts-
medizin Berlin. For data acquisition, 260–300MBq of FBB
PET tracer will be administered intravenously. Participants
will undergo a static scan at 90–110min after injection and
images will be consistently reconstructed according to the
current procedure guideline on brain PET imaging of the
German Society of Nuclear Medicine [76].
The FBB PET scans will be processed using an automated
pipeline based on the routines of the SPM software pack-
age, implemented in a MATLAB environment (Mathworks,
Inc., Nattick, MA, USA). For each PET scan, intra-PET mo-
tion correction, construction of static standardized uptake
value (SUV) images, and correction for partial volume ef-
fects using the Müller-Gärtner method [77] as imple-
mented in the PETPVE12 toolbox [78] will be performed.
Intensity scaling using the cerebellar cortex as reference re-
gion [79] will be applied to obtain standardized uptake
value ratio (SUVr) images. Neocortical Aβ-plaques burden
will be evaluated as the average FBB SUVr within a prede-
fined composite of cortical regions-of-interest [76]. In
addition, exploratory voxel-by-voxel analyses will be per-
formed on the FBB SUVr images.
Data management and monitoring
Documentation using a paper-based case report form
(CRF) will be implemented. To certify excellent data
Table 2 Neuroimaging data acquisition parameters
Sequence Main parameters [orientation, TR/TE/TI, FOV, slices, voxel size]
Structural sequences
T1 MPRAGE Sagittal, TR/TE/TI = 1900/2.52/900 ms, 256 × 256mm2, 192 slices, 1.0 × 1.0 × 1.0 mm3
FLAIR Axial, TR/TE = 11,000/97ms, 230 × 230mm2, 50 slices, 1.2 × 1.2 × 2.5 mm3
DTI Axial, TR/TE = 7500/86ms, 220 × 220mm2, 61 slices, 2.3 × 2.3 × 2.3 mm3, 64 directions (b = 1000)
High-resolution hippocampus TSE Coronar, TR/TE = 8020/48 ms, 150 × 150mm2, 24 slices, 0.4 × 0.4 × 2.0 mm3
Functional sequences
Resting-state fMRI Axial, TR/TE = 2300/30ms, 192 × 192mm2, 34 slices, 3.0 × 3.0 × 4.0 mm3
Task-related fMRI Axial, TR/TE = 2000/30ms, 192 × 192mm2, 32 slices, 3.0 × 3.0 × 3.0 mm3
pCASL Axial, TR/TE = 4300/19ms, 192 × 192mm2, 22 slices, 3.0 × 3.0 × 5.0 mm3, LD/PLD = 1.5/1.5 s
Abbreviations: DTI diffusion tensor imaging, FLAIR fluid-attenuated inversion recovery, fMRI functional magnetic resonance imaging, FOV field of view, LD labeling
duration, MPRAGE magnetization-prepared rapid acquisition gradient echo, pCASL pseudo-continuous arterial spin labeling, PLD post-label delay, TE echo time, TI
inversion time, TR repetition time, TSE turbo spin echo
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quality, a good clinical practice (GCP) monitoring will
be held on a regular basis. The SmartAge research team
will be responsible for data management under the guid-
ance of the principal investigator (AF). All CRF data will
be entered into an electronic database with following
quality control procedures: (a) double scoring and
double entry of data points in the paper-based records
and electronic records and (b) frequency distribution
checks of outcome measures (not stratified by interven-
tion group) to identify questionable data points.
Adverse events monitoring and reporting
The occurrence of AEs and SAEs will be constantly
monitored throughout the SmartAge trial. Participants
will be instructed to immediately contact the research
team in case of any self-noticed health changes or unex-
pected medical care visits. In addition, participants will
receive a study pass, which informs about participation
in the SmartAge trial and provides contact information
in case of an SAE/hospitalization. All AEs and SAEs will
be reported to and documented by the responsible study
physician (SAEs within 24 h).
In general, the risk of health damage due to spermi-
dine supplementation can be expected to be minimal,
based on a prior interventional report [35] and our
safety study [36]. Participants will be informed about all
possible risks and can withdraw consent at any time
without providing reasons. The expected “dropout” rate
will be balanced in advance by the number of
participants.
In case an SAE occurs, the study physician will first
make an assessment as to whether or not a causal rela-
tionship with the intake of the investigational supple-
ment is considered possible. Since this is a
double-blinded trial, the assessment will be done with-
out knowledge of group affiliation (spermidine and pla-
cebo). Emergency unblinding is possible, if the decision
on follow-up medical treatment may depend on the par-
ticipant’s allocated intervention during the trial. If more
than three of the enrolled participants suffer from SAEs
that are likely to be associated with spermidine intake
(as assessed by the study physician), the SmartAge trial
will be discontinued. All SAEs (whether or not related to
the intervention) and all relevant pseudonymized docu-
mentation related to the SAE will be documented in the
SAE report form, dated and signed by the principal in-
vestigator and included in the CRF documentation.
Statistical methods
Statistical analyses of the primary outcome and second-
ary outcomes will be specified in the statistical analysis
plan, to be written and registered before breaking the
blind of study investigators. Statistical analyses of the
primary outcome will be conducted by a designated
statistician. Statistical analyses of secondary outcomes
and additional exploratory analyses will be carried out
by study investigators.
The primary outcome will be analyzed using an
“intention to treat” (ITT) approach, consisting of all par-
ticipants randomized into the trial, regardless of length
of intervention. Subsequently, a “per protocol” analysis
is carried out, including only those participants, who fin-
ished the 12-month intervention period. We will assess
the between-group difference in the change of memory
performance, operationalized by mnemonic discrimin-
ation performance, between baseline (V1) and the end of
intervention (V2). Statistical analysis will be performed
using an ANCOVA model with the change in memory
performance (V2–V1) as dependent variable, interven-
tion group as independent variable, and baseline mem-
ory performance as well as age as co-variates. Analyses
of secondary endpoints will be conducted using compar-
able statistical methods. For example, analysis of change
in memory performance between baseline (V1) and
follow-up assessment (V3) will be carried out by means
of ANCOVA. In this model, change in memory perform-
ance (V3–V1) will represent the dependent variable,
with intervention group as the independent variable and
baseline scores and age inserted as covariate.
In case of missing primary endpoints, the primary ana-
lysis will be done by using multiple imputation methods.
It will further be investigated whether demographic or
biological factors are associated with primary and sec-
ondary endpoints and / or modulate the response to the
intervention, by integrating these variables into statistical
models as covariates (or as interactive term with the
intervention group). The main hypothesis is tested at a
two-sided significance level of alpha = 0.05, using the
ITT data set with multiple imputation.
Dissemination policy
Results of the SmartAge trial will be distributed to scientific
researchers and health-care professionals using peer
reviewed journals and presentations (oral and written) at
national and international scientific conferences. Publica-
tions will follow international recommendations of “Uni-
form Requirements for Manuscripts Submitted to
Biomedical Journals” (http://www.icmje.org/recommenda-
tions/). Results will also be made available for scientific and
lay audiences on the ClinicalTrials.gov website (Registered
in ClinicalTrials.gov with the Identifier NCT03094546). In
addition, we will transmit findings to the general population
and key stakeholders using media coverage, such as news-
paper articles and radio/television interviews.
Discussion
This is the first randomized controlled phase IIb trial to
determine potential beneficial impacts of a 12-month
Wirth et al. Alzheimer's Research & Therapy           (2019) 11:36 Page 12 of 17
nutritional spermidine supplementation on memory per-
formance in older individuals at risk for the develop-
ment of AD. In addition, we will assess memory
performance at 18 months and outcome measures of
other neurocognitive domains as well as behavioral and
physiological parameters to evaluate further benefits of
the intervention.
The target group of the SmartAge trial comprises cogni-
tively unimpaired older individuals with SCD. Given the fact
that this population is at higher risk of objective cognitive de-
cline and clinical progression [7, 8, 15], it is the key goal of
this study to contribute to the development of effective pre-
vention strategies. Our initial short-term (3months) phase
IIa trial demonstrated that spermidine supplementation is an
easy-to-use, safe, and well-tolerated intervention [36]. Based
on existing findings in animals and in humans [30, 32, 37],
oral spermidine intake may be expected to protect memory
performance and, as a consequence, favor perceived quality
of life in older individuals with SCD.
There are several caveats that are important to ac-
knowledge. Subjective cognitive decline is a heteroge-
neous condition that likely includes different etiologies
as well as individuals, who will experience objective cog-
nitive decline, while others remain stable for a long
period of time. Although significant progression has
been made to establish diagnostic criteria for SCD, there
is no universal standard for the operationalization of
SCD in clinical trials [80]. We have followed the existing
guidelines and recommendations by the international
SCD-I working group for studies on SCD [15] and ex-
amined other major SCD characterization cohort studies
[81]. Likewise, cutoff scores for cognitive abilities are not
strictly defined in the field, with cognitive deficits vary-
ing between 1 and 2 standard deviations below the nor-
mative mean [82]. Based on the literature review, we
chose to use a 1.5 standard deviations cutoff to define
cognitive abnormality, in line with other major SCD
studies in the field [59]. Therefore, conceivably some of
the recruited participants in this trial will be on the
lower spectrum of cognitive abilities, close to mild cog-
nitive impairment. Strengths of using a “more liberal”
cognitive threshold include increased average rates of
cognitive decline over the intervention period. We have
further enriched our sample characterization through
AD biomarkers, such as brain Aβ status (available for a
sub-sample) and genetic risk factors. On the basis of this
information, moderator analyses will be performed to es-
timate the effect of these AD variables on the interven-
tion outcomes.
Other limitations of this phase IIb trial include the time
period of intervention, which is still relatively short given the
slow evolution of AD pathogenic processes in
non-demented older individuals [83], and the restricted
number of participants. Larger multi-center phase III trials
with 1000–2000 participants and trial durations of 1.5–2
years commonly select clinical outcome measures, which are
however less sensitive [84]. We deliberately chose a highly
sensitive performance-based outcome measure, given our
relatively short intervention time and manageable number of
subjects. Although we recognize the importance of larger
sample sizes, we remain optimistic that any subtle cognitive
changes in our at-risk population will be detected based on
our previous phase IIa trial [37]. Lastly, it is important to
highlight that a multi-center trial implementation was not fi-
nancially attainable. Pending the positive results of this trial,
public funding for a phase III trial will be applied for, to
move this intervention into clinical routine.
Overall, the SmartAge trial aims to contribute to the
establishment of an effective and well-tolerable nutrition
intervention to promote brain and cognitive health in
older individuals at higher risk of dementia. A positive
outcome with regard to memory performance in the
spermidine-treated group may initiate a large
multi-center phase III trial with a profound impact on
public health, patients with SCD, and their families.
Trial status
Recruitment of participants started in January 2017 and
is expected to run until March 2019. The last follow-up
is scheduled for September 2020.
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